Phosphorus-containing inhibitors of angiotensin-converting enzyme. 1982

E D Thorsett, and E E Harris, and E R Peterson, and W J Greenlee, and A A Patchett, and E H Ulm, and T C Vassil

Several phosphonamides, phosphoramides, and phosphates having the general structure R-Y-P(O)(OH)-X-CH(CH3)-CO-Pro have been synthesized and tested for inhibition of angiotensin-converting enzyme (dipeptidyl carboxypeptidase; peptidyl-dipeptide hydrolase, EC 3.4.15.1). Inhibition was found to depend on the nature of R, Y, and X such that the maximal effect was observed when X = NH, Y = CH2, and R = phi CH2 (50% inhibition at 7 nM). Substitution of CH2 or O at X and O at Y produced significantly less potent inhibitors. Groups shorter or longer than R = phi CH2 led to less active inhibitors, presumably due to nonoptimal interaction of the side chain with the S1 subsite.

UI MeSH Term Description Entries
D009943 Organophosphorus Compounds Organic compounds that contain phosphorus as an integral part of the molecule. Included under this heading is broad array of synthetic compounds that are used as PESTICIDES and DRUGS. Organophosphorus Compound,Organopyrophosphorus Compound,Organopyrophosphorus Compounds,Compound, Organophosphorus,Compound, Organopyrophosphorus,Compounds, Organophosphorus,Compounds, Organopyrophosphorus
D010710 Phosphates Inorganic salts of phosphoric acid. Inorganic Phosphate,Phosphates, Inorganic,Inorganic Phosphates,Orthophosphate,Phosphate,Phosphate, Inorganic
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D006020 Glycopeptides Proteins which contain carbohydrate groups attached covalently to the polypeptide chain. The protein moiety is the predominant group with the carbohydrate making up only a small percentage of the total weight. Glycopeptide
D000806 Angiotensin-Converting Enzyme Inhibitors A class of drugs whose main indications are the treatment of hypertension and heart failure. They exert their hemodynamic effect mainly by inhibiting the renin-angiotensin system. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility. ACE Inhibitor,ACE Inhibitors,Angiotensin Converting Enzyme Inhibitor,Angiotensin I-Converting Enzyme Inhibitor,Angiotensin-Converting Enzyme Inhibitor,Kininase II Inhibitor,Kininase II Inhibitors,Angiotensin I-Converting Enzyme Inhibitors,Angiotensin-Converting Enzyme Antagonists,Antagonists, Angiotensin-Converting Enzyme,Antagonists, Kininase II,Inhibitors, ACE,Inhibitors, Angiotensin-Converting Enzyme,Inhibitors, Kininase II,Kininase II Antagonists,Angiotensin Converting Enzyme Antagonists,Angiotensin Converting Enzyme Inhibitors,Angiotensin I Converting Enzyme Inhibitor,Angiotensin I Converting Enzyme Inhibitors,Antagonists, Angiotensin Converting Enzyme,Enzyme Antagonists, Angiotensin-Converting,Enzyme Inhibitor, Angiotensin-Converting,Enzyme Inhibitors, Angiotensin-Converting,II Inhibitor, Kininase,Inhibitor, ACE,Inhibitor, Angiotensin-Converting Enzyme,Inhibitor, Kininase II,Inhibitors, Angiotensin Converting Enzyme
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D013379 Substrate Specificity A characteristic feature of enzyme activity in relation to the kind of substrate on which the enzyme or catalytic molecule reacts. Specificities, Substrate,Specificity, Substrate,Substrate Specificities

Related Publications

E D Thorsett, and E E Harris, and E R Peterson, and W J Greenlee, and A A Patchett, and E H Ulm, and T C Vassil
April 1990, American journal of hypertension,
E D Thorsett, and E E Harris, and E R Peterson, and W J Greenlee, and A A Patchett, and E H Ulm, and T C Vassil
January 1995, Journal de pharmacie de Belgique,
E D Thorsett, and E E Harris, and E R Peterson, and W J Greenlee, and A A Patchett, and E H Ulm, and T C Vassil
September 1987, The Medical clinics of North America,
E D Thorsett, and E E Harris, and E R Peterson, and W J Greenlee, and A A Patchett, and E H Ulm, and T C Vassil
May 1992, AACN clinical issues in critical care nursing,
E D Thorsett, and E E Harris, and E R Peterson, and W J Greenlee, and A A Patchett, and E H Ulm, and T C Vassil
July 2006, Ceska a Slovenska farmacie : casopis Ceske farmaceuticke spolecnosti a Slovenske farmaceuticke spolecnosti,
E D Thorsett, and E E Harris, and E R Peterson, and W J Greenlee, and A A Patchett, and E H Ulm, and T C Vassil
September 2011, Journal of clinical hypertension (Greenwich, Conn.),
E D Thorsett, and E E Harris, and E R Peterson, and W J Greenlee, and A A Patchett, and E H Ulm, and T C Vassil
November 1980, American family physician,
E D Thorsett, and E E Harris, and E R Peterson, and W J Greenlee, and A A Patchett, and E H Ulm, and T C Vassil
February 1988, British medical journal (Clinical research ed.),
E D Thorsett, and E E Harris, and E R Peterson, and W J Greenlee, and A A Patchett, and E H Ulm, and T C Vassil
December 1989, American heart journal,
E D Thorsett, and E E Harris, and E R Peterson, and W J Greenlee, and A A Patchett, and E H Ulm, and T C Vassil
July 1987, Soins; la revue de reference infirmiere,
Copied contents to your clipboard!